Kaposi’s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Kaposi’s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 6, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-11-19
DOI
10.1186/s40425-018-0437-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rapid Progression of Adult T-Cell Leukemia–Lymphoma after PD-1 Inhibitor Therapy
- (2018) Lee Ratner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series
- (2018) Lillian Sun et al. Journal for ImmunoTherapy of Cancer
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
- (2017) Robert Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases
- (2017) Ashlyn S. Everett et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma
- (2017) Charlotte Rigaud et al. PEDIATRIC BLOOD & CANCER
- Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma
- (2017) Gustavo Schvartsman et al. Journal for ImmunoTherapy of Cancer
- Nivolumab for Refractory Anaplastic Large Cell Lymphoma: A Case Report
- (2016) Holger Hebart et al. ANNALS OF INTERNAL MEDICINE
- Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
- (2016) Igor Puzanov et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- (2016) Alexander M. Lesokhin et al. JOURNAL OF CLINICAL ONCOLOGY
- Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
- (2016) Hasan Rehman et al. Journal for ImmunoTherapy of Cancer
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- "Eczema Coxsackium" and Unusual Cutaneous Findings in an Enterovirus Outbreak
- (2013) E. F. Mathes et al. PEDIATRICS
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started